To evaluate TGF-β signaling inhibition in vivo, we administered 6 mg/kg A8301 or a vehicle control to mice bearing 67C-4 tumors every other day and collected tumor samples for immunoblot analysis on Day 5. This evidence concerns the gene TGFB1 and neoplasm.